Amitiza Antitrust Class Action Against Takeda and Other Pharmaceutical Companies
Takeda Pharmaceuticals, Sucampo Pharmaceuticals, and Par Pharmaceutical · Amitiza and generic equivalents · Other
About this case
A class-action lawsuit by purchasers of Amitiza and its generic equivalents alleged that Takeda Pharmaceuticals, Sucampo Pharmaceuticals, and Par Pharmaceutical entered into an unlawful reverse-payment arrangement that delayed generic competition and caused overcharges. Following a five-week trial, a jury returned a verdict finding liability and awarded $474.89 million in pre-trebling damages to direct purchasers; separate damages were awarded to end payers and retailers, and further procedural developments are not specified.
Case overview
- Defendant company
- Takeda Pharmaceuticals, Sucampo Pharmaceuticals, and Par Pharmaceutical
- Product or service
- Amitiza and generic equivalents
- Case status
- Other
- Lawsuit type
- Antitrust
- Reported harm
- Competition Pricing
Participation information
Availability is based on each listed participation option and its deadline.
No active participation options are currently listed.
This information does not determine whether you qualify for a case.
Sources
Public reporting associated with this case.